Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines

Area of Science:

• Oncology
• Pharmacology
• Clinical Trial Design

Background:

• The US FDA approved amivantamab and mobocertinib in 2021 for advanced NSCLC with EGFR exon 20 insertion mutations post-chemotherapy.
• These approvals were granted via the accelerated approval pathway, raising questions about the established "unmet need" criteria.

Purpose of the Study:

• To critically evaluate the "unmet need" justification for the accelerated approval of amivantamab and mobocertinib.
• To assess the validity of current National Comprehensive Cancer Network (NCCN) guidelines recommending sequencing these drugs.
• To analyze the potential impact of these approvals on future clinical trial enrollment and drug development.

Main Methods:

• Review of FDA accelerated approval criteria and relevant clinical data.
• Analysis of NCCN guideline recommendations and supporting evidence.
• Discussion of post-marketing requirements and their implications for clarifying drug efficacy.

Main Results:

• Evidence suggests equipoise exists between the new targeted therapies and previously available treatment options.
• NCCN sequencing recommendations for these drugs lack supporting clinical data.
• Post-marketing studies may not adequately resolve efficacy questions raised by the accelerated approvals.

Conclusions:

• The accelerated approval of amivantamab and mobocertinib for EGFR exon 20 NSCLC warrants further scrutiny regarding unmet need.
• Current treatment guidelines and drug sequencing recommendations require data-driven validation.
• Misguided incorporation of new therapies may hinder enrollment in crucial clinical trials for rare molecular targets.